Alexion Pharmaceuticals Inc (ALXN) - Financial and Strategic SWOT Analysis Review

February 2021 | 65 pages | ID: A8983265F89EN
GlobalData

Abstracts

Alexion Pharmaceuticals Inc (ALXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Alexion Pharmaceuticals Inc (Alexion) discovers, develops and markets therapies based on complement biology and inhibition for rare diseases. The company’s portfolio spans complement inhibitors for the treatment of patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG), atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and neuromyelitis optica spectrum disorder (NMOSD) in anti-aquaporin-4 (AQP4) antibody positive patients. It also offers novel enzyme replacement therapies for patients with lysosomal acid lipase deficiency (LAL-D), hypophosphatasia (HPP), and ultra-rare metabolic disorders. Alexion is headquartered in New Haven, Connecticut, the US.

Alexion Pharmaceuticals Inc Key Recent Developments

Feb 04,2021: Alexion reports fourth quarter and full year 2020 results
Jan 12,2021: Alexion Highlights commercial, clinical and financial progress at the 39th annual J.P. Morgan Healthcare Conference
Dec 14,2020: AstraZeneca to acquire biopharmaceutical firm Alexion for $39bn
Oct 29,2020: Alexion reports third quarter 2020 results
Oct 06,2020: Alexion Highlights promising pipeline & distinguished rare disease capabilities at Virtual Investor Day

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

Table of Contents
List of Tables
List of Figures

SECTION 1 - ABOUT THE COMPANY

Alexion Pharmaceuticals Inc - Key Facts
Alexion Pharmaceuticals Inc - Key Employees
Alexion Pharmaceuticals Inc - Key Employee Biographies
Alexion Pharmaceuticals Inc - Major Products and Services
Alexion Pharmaceuticals Inc - History
Alexion Pharmaceuticals Inc - Company Statement
Alexion Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Alexion Pharmaceuticals Inc - Business Description
Product Category: Andexxa
Overview
Performance
Product Category: Kanuma
Overview
Performance
Product Category: Soliris
Overview
Performance
Product Category: Strensiq
Overview
Performance
Product Category: Ultomiris
Overview
Performance
Geographical Segment: Asia Pacific
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Others
Performance
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: The US
Performance
R&D Overview
Alexion Pharmaceuticals Inc - Corporate Strategy
Alexion Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Alexion Pharmaceuticals Inc - Strengths
Alexion Pharmaceuticals Inc - Weaknesses
Alexion Pharmaceuticals Inc - Opportunities
Alexion Pharmaceuticals Inc - Threats
Alexion Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Alexion Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 04, 2021: Alexion reports fourth quarter and full year 2020 results
Jan 12, 2021: Alexion highlights commercial, clinical and financial progress at the 39th annual J.P. Morgan Healthcare Conference
Oct 29, 2020: Alexion reports third quarter 2020 results
Oct 06, 2020: Alexion highlights promising pipeline & distinguished rare disease capabilities at Virtual Investor Day
Aug 25, 2020: Alexion Pharmaceuticals: Departure of directors or certain officer; election of directors
Aug 06, 2020: Alexion announces appointment of first Chief Diversity Officer
Jul 30, 2020: Alexion reports second quarter 2020 results
Jul 02, 2020: Alexion finalizes settlement with the U.S. Securities and Exchange Commission
Jul 02, 2020: SEC charges Alexion Pharmaceuticals with FCPA violations
Jun 17, 2020: Alexion Charitable Foundation announces first rare belonging grants

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Alexion Pharmaceuticals Inc, Key Facts
Alexion Pharmaceuticals Inc, Key Employees
Alexion Pharmaceuticals Inc, Key Employee Biographies
Alexion Pharmaceuticals Inc, Major Products and Services
Alexion Pharmaceuticals Inc, History
Alexion Pharmaceuticals Inc, Subsidiaries
Alexion Pharmaceuticals Inc, Key Competitors
Alexion Pharmaceuticals Inc, Ratios based on current share price
Alexion Pharmaceuticals Inc, Annual Ratios
Alexion Pharmaceuticals Inc, Annual Ratios (Cont...1)
Alexion Pharmaceuticals Inc, Annual Ratios (Cont...2)
Alexion Pharmaceuticals Inc, Interim Ratios
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Alexion Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Alexion Pharmaceuticals Inc, Performance Chart (2016 - 2020)
Alexion Pharmaceuticals Inc, Ratio Charts
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

COMPANIES MENTIONED

Regeneron Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Biogen Inc
Arvinas Inc
Novartis AG
Genzyme Corp
Baxter International Inc
DepYmed Inc
Amgen Inc